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There is increasing evidence that male or female genital tract represent a distinct replication compartment for human immunodeficiency
virus type 1 (HIV-1) and that such compartments may serve as a virus reservoir. Forty-four paired plasma and vaginal samples from HIV-
infected females undergoing HAARTwere collected to examine the viral responses to antiretroviral therapy and to assess the possible role of
the vaginal tract as a reservoir for drug-resistant variants. Twenty-one females had detectable viral RNA both in plasma and vaginal fluid,
whereas 14 females had detectable virus only in plasma. Twelve paired samples were used to analyze HIV-1 pol sequences for the presence of
drug resistance-associated mutations. Nine of the twelve paired samples exhibited discordant drug resistance mutation patterns. The other
three females showed identical drug resistance-associated mutations. However, further examination of protease and RT showed numerous
non-drug-associated mutations that corresponded to predefined CTL epitopes. These non-drug-associated mutations were different between
plasma and vaginal viruses, suggesting that evolution of HIV-1 was independent in these two compartments.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV-1; HAART; Drug resistance; Virus compartmentalization
Introduction 1999). However, HAART has been unable to eradicate theThe human immunodeficiency virus (HIV)-related mor-
tality and morbidity has been significantly reduced by highly
active antiretroviral therapy (HAART) (Alexander et al.,
2003; De Rossi, 2002; Gulick et al., 1997; Hammer et al.,
1997; Kaufmann and Cooper, 2000; Palella et al., 1998;
Pomerantz, 2002; Pomerantz, 2003; Saksena and Haddad,
2003; Saksena and Potter, 2003) because majority of the
individuals receiving HAART develop undetectable viral
RNA in plasma (<50 copies/ml) (Hirschel and Opravil,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: akumar@psm.edu (A. Kumar).virus due to virus hiding in the reservoirs, and also that it may
not be exposed to critical level of the antiretrovirals. Resting
CD4+ T cells (Chun et al., 2003; Gondois-Rey et al., 2001;
Hermankova et al., 2003; Karlsson et al., 2001; Persaud et al.,
2000; Pomerantz, 2003; Shen et al., 2000; Siliciano et al.,
2003; van Rij et al., 2002) and monocytes/macrophages
(Aquaro et al., 2002a, 2002b; Crowe et al., 2003; Fischer-
Smith et al., 2001; Garbuglia et al., 2001; Smith et al., 2003)
are examples of such reservoirs where virus continues to
replicate in the individuals receiving HAART. This has
limited the usefulness of HAART and resulted into emer-
gence of drug-resistant strains of the virus. The kinetics of
emergence of the drug-resistant strains of the virus may vary
in diverse anatomical compartments and this variation can be
attributed to the different pharmacokinetic properties of a
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1997a, 1997b). Furthermore, several compartments such as
cerebrospinal fluid (Hoetelmans, 1998; Lafeuillade et al.,
2002), genital tract secretions (Lafeuillade et al., 2002;
Overbaugh et al., 1996), and lymphoid tissue (Lafeuillade
et al., 2002; Omrani and Pillay, 2000) have been shown to be
poorly accessible by different antiretroviral drugs.
In recent years, different anatomical compartments have
been the focus of attention as related to evolution of HIV-1 in
different environments, and also for the emergence of drug
resistance strain of the virus. Several studies have identified
differential composition of virus recovered from plasma and
peripheral blood mononuclear cells (PBMC) (Livingstone et
al., 1996; Simmonds et al., 1991) during HIV-1 infection. The
virus has also been found to evolve differently in a variety of
other compartments as discordant viral sequences have been
reported between PBMC and mucosal (rectal and cervical)
compartments (Poss et al., 1995, 1998; Zhang et al., 2002);
PBMC and renal epithelial cells (Marras et al., 2002); blood
and breast milk (Becquart et al., 2002); blood and semen
(Delwart et al., 1998; Kiessling et al., 1998), brain, spleen,
and lymph node (Wong et al., 1997a, 1997b). Furthermore,
drug-induced compartmentalization of HIV-1 has also been
shown in plasma and PBMC (Wang et al., 2000) as well as
different cell types like CD4+ T cells, CD8+ T cells, and
monocyte/macrophage (Potter et al., 2003).
The virus in the female genital tract may be very
important for both vertical (mother-to-child) and heterosex-
ual (female-to-male) transmission. Antiretroviral treatment
does not eradicate HIV-1 from the cervicovaginal compart-
ment; nevertheless, it has been found to be associated with
reduced amounts of viral RNA in the female genital
secretions (Cu et al., 1998; Cu-Uvin et al., 2000; Dornadula
et al., 1999; Hart et al., 1999; Rasheed et al., 1996), leading
to a significant decline in perinatal transmission (Doren-
baum et al., 2002; McGowan and Shah, 2000). In the
present study, we sought to determine emergence of the
drug resistance pattern in the virus from vaginal secretion
and plasma of HIV-1-infected women. In the event of
identical drug resistance pattern, the virus was further
characterized for possible compartmentalization based on
other regions in the protease and reverse transcriptase (RT).Results
Viral load in plasma and genital secretion
Blood and vaginal samples were collected from a total of
44 females. Nine subjects (20%) did not have detectable viral
loads (VL) in both plasma and vaginal secretions. Fourteen
subjects (31%) had detectable plasma but undetectable virus
in vaginal secretions, whereas 21 females (46.6%) had
detectable viruses in both plasma and vaginal secretions.
The VLwas <1000 RNA copies Eq/ml in 19 (42.2%) plasma,
and 31 (68.8%) vaginal samples (Data not shown).Paired plasma and vaginal secretions from 12 HIV-
infected females were analyzed for pol sequence. The
selection criteria for these 12 patients included continuous
treatment at the time of sample collection. There were some
naı¨ve patients (n = 3) and others who were on drug holiday
at the time of sample collection (n = 7). There were other
groups of patients (n = 12) where either sufficient vaginal
sample was not available or we failed to amplify the portion
of pol because of low viral load. The demographic, clinical,
and virologic profiles of these samples are shown in Table 1.
The CD4 T-cell counts ranged from 15 to 1088 cells/Al of
blood (mean 251). The plasma viral load ranged from
undetectable level in one woman to >750000 RNA Eq
copies/ml (mean 147300 RNA Eq copies/ml in 11 women).
Vaginal viral load ranged from <50 RNA copies Eq/ml in
one woman to 96781 RNA copies Eq/ml (mean 10798
RNA Eq copies/ml in 11 women). There was only a
moderate degree (Pearson’s correlation of 0.502) of corre-
lation between (log) vaginal and plasma HIV-1 viral loads.
In 10 of 11 women where virus was detectable in both
compartments, VL was 7- to 324-fold lower in vaginal
compartment. Only exception to this trend was subject
32A who had 3.2 higher VL in vaginal secretion than that
in plasma. Generally, there was inverse relationship between
CD4 counts and VL.
Emergence of drug-resistant virus in HIV-1-infected women
Of 44 HIV-1-infected females, 29 plasma samples were
examined for drug-resistant variants of the virus in plasma
(Fig. 1). Other 15 samples could not be analyzed because of
either low viral load or limited sample availability. Eight
HIV-1-infected females (27.6%) did not show any drug
resistance associated mutations in protease and RT, whereas
21 (72.4%) women showed resistance to one or other class
of drugs. Nine women (31%) showed resistance to only one
class of ART (20.6% NRTI, 6.9% NNRTI, and 3.5% PI).
Likewise, nine women (28.5%) also showed double resis-
tance with seven women (24.1%) being resistant to PI and
NRTI and two (6.9%) resistant to the combination of NRTI
and NNRTI. Triple resistance was least common and only 3
of 28 females (10.7%) showed resistance to PI, NRTI, and
NNRTI. Most common primary mutations in the plasma
virus (n = 29) included L90M (17.1%), V82A (14.3%), and
M46I/L (14.3%) in the protease, and M184V and T215F
(34.3%), K103N and K70R (20.0%) and D67N (22.9%) in
the RT (results not shown).
Comparison of drug resistance in plasma and vaginal
viruses
Twelve females were examined for drug resistance pat-
tern in free viruses collected from plasma and vaginal
compartment. They showed two distinct patterns. A group
of nine females (75%) showed discordant drug resistance
pattern in the two compartments, whereas second group of
Table 1
Demographic, clinical, and virologic profiles of study subjects
Patient
ID
Age/
risk
factora
Year HIV
diagnosis
Time
since
AIDS
(year)b
CD4,
Count,
(cells/Al)c
Plasma,
VL,
(RNA
copies
Eq/ml)d
Vaginal,
VL, (RNA
copies
Eq/ml)e
Antiretroviral drug history and
year commencedf
Current treatment
32A 48/H 1991 No 529 350 1113 1992: d4T, 3TC, IDV d4T + 3TC + IDV
33B 35/H 1999 0.83 189 <50 <50 1999: AZT, 3TC, IDV, NFV AZT + 3TC + NFV
36E 39/H 1993 No 1088 15749 450 1990: AZT, ddC, ddI, d4T,
3TC, RTV, IDV, NFV
d4T + 3TC + NFV
41J 39/H 1996 Yes
(N/A)
206 24022 918 1996: AZT, ddC, ddI, d4T,
3TC, IDV, NFV, SQV
EFV + 3TC + d4T
008 31/H 1994 0.17 16 275370 850 1995: AZT, ddC, ddI, d4T,
3TC, IDV, NFV, SQV, RTV,
NFV, EFV
ABC + DLV + APV
012 46/H 1994 7 22 >750000 96781 2001: d4T, 3TC, IDV, SQV d4T + 3TC + LPV/RTV
016 34/H 1991 5 24 140704 2.745 1998: d4T, 3TC, IDV, ddI, NFV AZT + EFV + APV
034 32/H, T 1994 No 311 54829 7998 1996: AZT, ddI, d4T, 3TC, IDV d4T + 3TC + IDV
020 40/H 1997 5 157 40135 578 2001: N/A AZT + 3TC + EFV
42K 39/H 1999 0.16 229 96843 4403 1999: AZT, ddI, ddC, d4T, 3TC,
SQV, NFV, EFV
AZT + 3TC
006 47/H 1992 5 226 109561 1436 1997: 3TC, AZT, IDV, others ddI + d4T + NFV
025 41/H 1992 7 15 112737 1513 1999: 3TC, d4T, NFV, LPV, RTV 3TC + d4T + LPV/RTV
a Risk factor H = heterosexual, T = blood transfusion.
b Individuals were clinically diagnosed for AIDS based on CD4 counts <200/Al blood or recurrence of opportunistic infections. Individuals with NO have not
progressed to clinical disease phase. One subject (41J) was diagnosed with AIDS based on clinical symptoms when she enrolled in our clinic. However, exact
time for clinical phase could not be determined because of unavailability medical records.
c Percentage of CD4 T cell counts were determined by flow cytometry and absolute CD4 T cell counts were calculated by multiplying the CD4 T cell
percentage with absolute lymphocyte count.
d Plasma viral load (VL) was determined by Amplicor assay (Roche Diagnostics Corp.).
e Vaginal viral RNA load was determined by Amplicor assay (Roche Diagnostics Corp.). Since vaginal secretion was diluted 8.5 times, therefore viral load in
vaginal fluid is expressed as assay value  8.5.
f Antiretroviral usage history was not available for one woman (ID: 020). d4T, stavudine; 3TC, lamiduvine; IDV, indinavir; AZT, zidovudine; NFV, nelfinavir;
ddC, zalcitabine; ddI, didanosine; RTV, ritonavir; SQV, saquinavir; EFV, efavirenz; APV, amprenavit; LPV, lopinavir. Treatment history was not available for
patient 020.
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resistance-associated mutations.
Development of drug resistance in the females that showed
discordant pattern between plasma and vaginal virus
Different drug-associated mutations in the RT and prote-
ase gene of plasma and vaginal viruses from nine females
are shown in Figs. 2 and 3, respectively. The plasma and
vaginal virus from two subjects (012 and 42K) showed
identical number of mutations in RT and protease genes
together. However, these mutations were different in indi-
vidual compartments of each subject suggesting differential
evolution of drug resistance in the two compartments. Four
of nine females (32A, 43L, 020, and 36E) showing discor-
dant mutations exhibited 1.4- to 7-fold more mutations in
the plasma virus than that in the vaginal virus. Plasma virus
from 32A showed three mutations in RT and five mutations
in protease, whereas vaginal virus showed no mutation in
protease and only one mutation in RT. This again suggests
that virus evolved differently in the two compartments of
this patient. The other three patients in this category
exhibited similar pattern of virus evolution, suggesting thatemergence of drug resistance was slower in the vaginal
compartment. Two other females (33B and 034) did not
show any drug resistance-associated mutation in the reverse
transcriptase, whereas virus collected from either compart-
ment developed drug resistance-associated mutations in the
protease. Patient 008 also exhibited distinct mutations in
protease and RT genes but the vaginal virus showed more
drug resistance-associated mutations than those seen in the
plasma virus.
We also analyzed the treatment history of females show-
ing ‘‘discordant’’ drug resistance-associated mutation with
particular emphasis on M184V and T215Y mutations. Two
females (012 and 036E) showed T215Y mutation in the
vaginal but not in the plasma virus, even 2 and 4 years after
stopping zidovudine. One of them (012) also had M184V
mutation in vaginal but not in plasma HIV-1. This mutation
was present several months after cessation of 3TC treatment.
Development of drug resistance in the females that showed
identical pattern between plasma and vaginal virus
Three of twelve females examined for this study showed
identical drug resistance-associated mutations in the reverse
Fig. 1. HIV-1 drug resistance pattern in plasma. A total of 29 plasma
samples from HIV-infected females were examined for drug-associated
mutations. Viral RNAwas extracted from plasma using QIAamp viral RNA
kit (Qiagen Inc.). A 1.3-kb pol fragment was amplified and sequenced using
TruGene HIV-1 genotyping kit (Bayer). Codons 1–99 (protease) and 39–
244 (RT) were detected with the OpenGene system and resistance pattern
was generated using GuideLines 6.0 (updated 8/2002). The resistance
pattern was identified against nucleoside reverse transcriptase inhibitor
(NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and
protease inhibitor (PI). The results are expressed in percentage of the
HIV-infected females demonstrating single, double, or triple class of
antiretrovirals. Dash denotes same amino acid as in parent sequence used
for comparison.
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viruses collected plasma and vaginal compartment. Patient
41J showed two drug resistance-associated mutations, one
each in RT and protease. The plasma and vaginal viruses
from patient 006 and 025 showed a total of 14 and 12
identical drug resistance-associated mutations, respectively.Fig. 2. Deduced amino acid sequences of HIV-1 reverse transcriptase (RT) in paire
mutations. Viral RNAwas extracted from plasma and vaginal compartment as des
determined as described in Fig. 1. The sequence showing more than one amino ac
sequences from nine HIV-infected females were aligned with respective sequence
sequence used for comparison.HIV-1-infected females showing identical drug-associated
mutations in protease and RT showed differences in other
regions
Because three women showed identical drug-associated
mutations in the viruses collected from the plasma and
vaginal compartment, we examined other regions of RT
and protease to determine whether virus evolution was
identical in these two compartments. The changes in RT
and protease are shown in Figs. 6 and 7, respectively. All
three females showed numerous silent mutations as well as
changes at amino acids level, suggesting that the evolution
rate of the virus was different in these two compartments.
Both plasma and vaginal viruses from Patient 41J showed
three and six mutations at the amino acid level in protease
and RT, respectively. However, vaginal viruses had a mixed
population containing wild type, too, suggesting that the
evolution of virus in this compartment was slow. Further-
more, 41J showed 12 and 11 silent mutations in RT of
plasma and vaginal viruses, respectively, and many of
these mutations were different in the two compartments.
The Protease gene of 41J virus showed two silent muta-
tions in plasma virus and one in vaginal virus. Likewise,
the other two females also showed numerous silent muta-
tions, and also at amino acids level both in plasma and
vaginal viruses of which several changes were distinct in
the two compartments.Discussion
This cross-sectional study examined the differences
between vaginal and plasma virus analyzing the drug-d plasma and genital samples showing discordant drug resistance-associated
cribed in Materials and methods. Drug resistance-associated mutations were
id at a particular location represents different quasi-species of the virus. The
from HIV-1LAI (on the top). Dash denotes same amino acid as in parent
Fig. 3. Deduced amino acid sequences of HIV-1 protease in paired plasma and genital samples showing discordant drug resistance-associated mutations. Viral
RNA was extracted from plasma and vaginal compartment as described in Materials and methods. Drug resistance-associated mutations were determined as
described in Fig. 1. The sequence showing more than one amino acid at a particular location represents different quasi-species of the virus. The sequences from
nine HIV-infected females were aligned with respective sequence from HIV-1LAI (on the top). Dash denotes same amino acid as in parent sequence used for
comparison.
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We found that 9 of the 12 females (75.0%) showed
discordant mutation patterns between vaginal and plasma
cell-free HIV-1. The heterogeneity between plasma and
vaginal cell-free HIV-1 Pol sequences in ‘‘discordant’’
females suggests differential evolution of the virus in
two compartments. Treatment history of the ‘‘discordant’’
cases showed delayed clearance of resistant mutants from
their vaginal HIV-1 population. We do not have a direct
evidence for this delayed clearance, and our conclusion is
based on the fact that zidovudine-associated mutation was
present in the vaginal virus from two patients even after
2–4 years after cessation of zidovudine therapy. Three
females with identical drug-associated mutations also
showed differential evolution of the viruses in the two
compartments as evident by presence of different non-
drug-associated mutations in pol of viruses collected from
plasma and vaginal compartment.
There seems to be a general notion that HIV-1 freely
circulates from the peripheral blood into the various bodyFig. 4. Comparison of deduced amino acids sequences in RT of the HIV-1, collecte
drug-associated mutations. Viral RNAwas extracted from plasma and vaginal com
mutations were determined as described in Fig. 1. The sequence showing more tha
the virus. The sequences from three HIV-infected females were aligned with respe
as in parent sequence used for comparison.tissues. However, it has been widely reported that HIV-1 in
the CNS (Gorry et al., 2001; Huang et al., 2002; Ross et al.,
2001; Staprans et al., 1999; Van Marle et al., 2002), mucosal
compartments (Poles et al., 2001), or the male genital tract
(Byrn and Kiessling, 1998; Gupta et al., 2000; Kiessling et
al., 1998; Zhu et al., 1996) are distinct from those viruses
found in the blood. However, there are contradicting reports
in the literature regarding development of drug resistance in
the blood and vaginal compartments of HIV-1-infected
females. A French study reported similar drug resistance-
associated mutations in plasma and vaginal virus (Si-
Mohamed et al., 2000). On the contrary, Ellerbrock et al.
(2001) reported discordant drug-associated mutations in the
virus in the two compartments. In the present study, we find
75% women showing discordant pattern whereas 25%
showing identical pattern, suggesting that there is no set
rule for the evolution of drug-resistant mutations. The
emergence of drug resistance might be influenced by several
other factors such as pharmacokinetics of a particular drug
in individual compartments (Kepler and Perelson, 1998).d from plasma and vaginal compartment of three females who had identical
partment as described in Materials and methods. Drug resistance-associated
n one amino acid at a particular location represents different quasi-species of
ctive sequence from HIV-1LAI (on the top). Dash denotes same amino acid
Fig. 5. Comparison of deduced amino acids sequences in protease of the HIV-1, collected from plasma and vaginal compartment of three females who had
identical drug-associated mutations. Viral RNAwas extracted from plasma and vaginal compartment as described in Materials and methods. Drug resistance-
associated mutations were determined as described in Fig. 1. The sequence showing more than one amino acid at a particular location represents different quasi-
species of the virus. The sequences from three HIV-infected females were aligned with respective sequence from HIV-1LAI (on the top). Dash denotes same
amino acid as in parent sequence used for comparison.
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yses than that published previously. Another reason for
discrepancy between this study and the French study might
be attributed to the fact that in the previous study, the
females were tested at the time of their first treatment
failure, whereas the present study population is generally
highly treatment experienced or in advanced stages of the
disease. Nevertheless, one-fourth of the HIV-infected
females still showed identical drug resistance-associated
mutations in the both compartments.
In the present study, three of nine discordant cases
showed substantially lower number of resistance mutations
in vaginal cell-free HIV-1 and appeared to show delayed
emergence of drug resistance in the vaginal compartment.
This conclusion is based on presence of drug resistance
mutations in plasma that were absent in the vaginal
compartments and also by an earlier report describingFig. 6. Comparison of deduced amino acids sequences in drug unrelated region of R
was extracted from plasma and vaginal compartment as described in Materials
described in Fig. 1. The sequence showing more than one amino acid at a particu
amino acid level is shown in bold, whereas silent mutations are shown in italics. T
sequence from HIV-1LAI (on the top). Dash denotes same amino acid as in paredelayed emergence of the drug resistance mutation in the
vaginal compartment (Ellerbrock et al., 2001). This study
provides further insights into the kinetics of drug resis-
tance-associated changes in RT and protease. In addition to
delayed emergence of drug resistance in the vaginal
compartment, we also observed that once drug resistance
mutations had appeared in the vaginal compartment, they
continued to be detectable for 2–4 years even after
discontinuation of that particular antiretroviral. On the
contrary, the same mutations were undetectable in the
plasma virus after cessation of treatment with the respec-
tive drug. Generally, rate of mutation in the plasma virus
was higher or equivalent than that in the vaginal virus.
However, in one case, vaginal virus showed more drug-
associated mutations.
Our second goal was to determine whether plasma and
vaginal viruses with identical drug resistance-associatedT in three females who had identical drug-associated mutations. Viral RNA
and methods. Drug resistance-associated mutations were determined as
lar location represents different quasi-species of the virus. Mutation at the
he sequences from three HIV-infected females were aligned with respective
nt sequence used for comparison.
Fig. 7. Comparison of deduced amino acids sequences in drug unrelated region of the protease in three females who had identical drug-associated mutations.
Viral RNAwas extracted from plasma and vaginal compartment as described in Materials and methods. Drug resistance-associated mutations were determined
as described in Fig. 1. The sequence showing more than one amino acid at a particular location represents different quasi-species of the virus. Mutation at the
amino acid level is shown in bold, whereas silent mutations are shown in italics. X denotes insertion of stop codon in the sequence. The sequences from three
HIV-infected females were aligned with respective sequence from HIV-1LAI (on the top). Dash denotes same amino acid as in parent sequence used for
comparison.
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or virus compartmentalization was defined through
changes in other regions not associated with drug resis-
tance. Our analysis revealed that virus in both compart-
ments evolved independently. There were numerous non-
drug-associated mutations present in those three females
and many of these mutations were different between
plasma and vaginal viruses. Furthermore, these mutations
corresponded to several CTL epitopes in RT and protease
described previously (Goulder and Walker, 1999; Walker
and Korber, 2001). Our results clearly showed that both
plasma and vaginal viruses had mutated in the regions
containing CTL epitopes. Therefore, it appears that both
selection of drug-resistant strains as well as possible
immunologically variants of the virus were contributing
factor to the virus evolution in these women.
In the present communication, we have also demon-
strated the presence of unique HIV-1 drug resistance
mutants in the vaginal compartment, suggesting that the
vaginal tract may serve as reservoir and may contribute to
the transmission of drug-resistant strains. This has some
important clinical implications in the risk of heterosexual
and perinatal transmission of HIV-1. The findings from
this study support the need to use genotype testing during
primary HIV infection. Further studies into the pharmaco-
kinetics of ART in body compartments including vaginal
tract are also needed to help understand the differences in
drug-associated mutations pattern and the evolution of HIV
in that compartment.Materials and methods
Study subjects
Paired blood and vaginal swab samples were collected
from 44 HIV-1 positive females, most of them receiving
antiretroviral therapy at several clinics in Puerto Rico. Viral
loads in plasma and vaginal secretions were assessed usingultrasensitive version of Amplicor HIV Monitor (Roche
Diagnostics Corp., New Jersey). CD4+ T-cell counts were
determined at time of sampling or within last 3 months of
sample collection.
The mean age of the study population was 40 years
(range 19–55). The majority of individuals (88.6%; 39/44)
reported heterosexual contact as a risk factor. Of these,
12.8% reported contact with an IVDU and 38.4% had
contact with a known HIV-1-infected male. Only two
females reported IV drug use including one who also
reported receiving a blood transfusion.
Twenty percent of the study population were on two
nucleoside analogs (NRTI) or a combination of NRTI and
non-nucleoside analog (NNRTI). Another group of 60%
females was on NRTI or NNRTI, whereas the remaining
subjects were either naı¨ve HIV case or not receiving any
treatment at the time of sample collection. A significant
proportion (75%) of 12 subjects, included in the study, were
suffering from AIDS at the time of first visit or soon
thereafter.
Sample preparation
Twenty-milliliter blood was collected from each female
of which a 200-Al aliquot was used for CD4+ T-cell count.
The remaining blood was centrifuged at 3000 rpm for 10
min to separate the plasma. Plasma was frozen at 85 jC
for determination of the viral load and protease and RT
sequencing. Vaginal secretion was collected by using two
Dacron-tipped applicators and taking swabs from cervico-
vaginal area. The swabs were vigorously washed in 2 ml
of R-10 (RPMI-1640, HEPES, and 10% human AB
plasma) to release the virus and loosen cells before being
removed from tubes. The amount of vaginal secretions
retained by each tip was calculated to be 133 Al by a dye
dilution method. The tubes containing vaginal swabs were
brought to the laboratory for processing within 3 h of
collection. Vaginal cells were separated by centrifugation
at 1000 rpm for 10 min and supernatants were filtered
G. Tirado et al. / Virology 324 (2004) 577–586584through a 0.2-Am pore membrane filter. All vaginal ali-
quots were frozen at 85 jC until used for virus load
determination and sequencing.
Viral load and CD4 assessments
Plasma and vaginal HIV-1 RNA viral loads were
assessed using the Amplicor HIV-1 Monitor test standard
specimen processing (Roche Diagnostics Corp.). The ultra-
sensitive specimen processing procedure was used to deter-
mine the viral load in the vaginal secretion since the
secretions were diluted 8.5-fold (i.e., 2  133 Al vaginal
fluid diluted in the final volume of 2266 Al medium). Viral
load in vaginal fluid was, therefore, expressed as (assay
value)  8.5. CD4 T-cell percentage was determined by
flow cytometry and absolute CD4 T cell number was
calculated using percentage of CD4 T cell count and
lymphocyte numbers per microliter of blood.
Sequencing of HIV-1 pol gene
HIV-1 RNA was isolated using the QIAamp viral RNA
Kit (QIAGEN, Inc., California). A 1.3-kb fragment of the
polymerase (pol) gene was amplified and sequenced using
the TruGene HIV-1 Genotyping Kit (Bayer Healthcare-
Diagnostic Div.) according to the manufacturer’s instruc-
tions. Bidirectional sequences of the protease (pro) gene
(codons 1–99) and most of the reverse transcriptase (RT)
gene (codons 39–244) were detected with the OpenGene
System (Bayer Healthcare-Diagnostic Div.). The resistance
pattern was generated using GuideLines 6.0 (updated Oct.
2002), provided by the supplier.Acknowledgments
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